Organovo Holdings and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction.
Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.
3M, a US-based manufacturing company, has agreed to sell almost all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650m.
UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced today that they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.
Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.
The Incheon Metropolitan City government announced an ambitious plan for developing the Songdo Global Biotech Cluster in the Incheon Free Economic Zone.
Merck has signed an agreement to acquire biopharmaceutical company ArQule for a total equity value of around $2.7bn.
XBiotech has agreed to offload its human antibody bermekimab to Janssen Biotech, a subsidiary of Janssen Pharmaceutical Company of Johnson & Johnson, in a deal worth up to $1.35bn.
Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a leading life sciences innovation fund.
Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s Artificial Intelligence (AI)-powered platform.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.